Improving Patient Outcomes in Acute Leukaemias: Navigating Complex Treatment Decisions in an Era of Novel Therapies
- Dr Jeroen Janssen1
Dr Jeroen Janssen,1 Dr Christoph Röllig,2 Dr Ryan Cassaday3
Dr Janssen has received research funding and/or honoraria from BMS, Incyte, Novartis, and Pfizer. He is the founder of HematologyApp, and supported by BMS, Daiichi Sankyo, Incyte, Janssen, MSD, Pfizer, Roche, and Takeda. Dr Röllig has received research grants and/or personal fees from AbbVie, Amgen, Astellas, Bayer, BMS, Celgene, Daiichi Sankyo, Janssen, Jazz, Novartis, Pfizer, and Roche. Dr Cassaday has received research support and/or advisory/honoraria from Amgen, Kite/Gilead, Merck, Pfizer, and Vanda Pharmaceuticals.
Medical writing assistance was provided by Sue Libretto Publications Consultant Ltd, Welwyn Garden City, UK.
The symposium and the publication of this article was funded by Pfizer. Pfizer reviewed the article for medical accuracy and provided feedback to the authors. All named authors had full editorial control of the paper and provided their final approval of the content.
- EMJ Hematol. 2019;7[Suppl 2]:2-7.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.